We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Four New Genes Added to Inherited Breast Cancer Risk List

By LabMedica International staff writers
Posted on 17 Jun 2014
Based on risk and frequency, three classes of breast cancer susceptibility genes or loci are currently recognized, but four more genes have been added the growing list of higher risk genes. More...


Before a cell becomes cancerous, a number of mistakes need to be present in its genetic code and these mistakes are referred to as mutations. It is possible to be born with a gene mutation that may increase the risk of cancer, this mutation does not mean the individual will categorically suffer from a form of cancer, but the individual will be more likely to develop cancer than the average person.

A team of scientists at Huntsman Cancer Institute at the University of Utah (Salt Lake City, UT, USA) who led an international consortium between 1995 and 2005 recruited 1,313 subjects all who were diagnosed with breast cancer at or before age 45 years. The 1,123 controls were frequency matched to the cases within each center on racial/ethnic group, with age at selection not more than ±10 years from the age range at diagnosis of the cases gathered from the same center.

The scientists used high resolution melt curve analysis followed by Sanger sequencing, and they screened for mutation in the coding exons and proximal splice junction regions of the meiotic recombination 11 homolog A (MRE11A)-RAD50 homolog (RAD50) –Nibrin (NBN) gene complex (MRN) in both populations. Rare variants in the three genes were pooled using bioinformatics methods similar to those previously applied to known breast cancer risk and then assessed the results by logistic regression. These three genes MRE11A, RAD50 and NBN were therefore shown to be intermediate-risk breast cancer susceptibility genes.


Sean Tavtigian, PhD, the lead author of the study said, “The breast cancer genes BRCA1 and BRCA2 aren't the whole story when it comes to inherited breast cancer risk. We've known for a long time that more genes had to be responsible, and several have since been discovered, by us and others. Originally, the gene we are currently studying, called RAD50 Interactor 1 (RINT1), was not considered a human cancer susceptibility gene. But then we discovered there was a two- to three-fold increase in risk for breast cancer in families that carry a mutation in that gene." The main study was published on June 3, 2014, in the journal Breast Cancer Research.

Related Links:

Huntsman Cancer Institute



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.